BioMarin signals $3.325B-$3.425B 2026 revenue target as acquisitions and pipeline drive growth
Source: SeekingAlpha
2026-02-23 23:15:27 ET
More on BioMarin Pharmaceutical
- BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
- BioMarin Pharmaceutical Inc. 2025 Q4 - Results - Earnings Call Presentation
- The Right Play On BioMarin Pharmaceuticals
- BioMarin Pharmaceutical Q4 2025 Earnings Preview
- BioMarin prices $850M senior notes, completes $2B term loan syndication
Read the full article on Seeking Alpha
For further details see:
BioMarin signals $3.325B–$3.425B 2026 revenue target as acquisitions and pipeline drive growth
BioMarin Pharmaceutical Inc.
NASDAQ: BMRN
BMRN Trading
-1.1% G/L:
$59.81 Last:
820,345 Volume:
$60.23 Open:
BMRN Latest News
February 27, 2026 08:00:00 pm
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
February 24, 2026 09:00:00 am
BioMarin to Participate in Four Upcoming Investor Conferences in March
BMRN Stock Data
$11,572,007,511
190,193,201
0.01%
214
N/A
Biotechnology & Life Sciences
Healthcare
US
San Rafael
